Extended indication Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
Therapeutic value No judgement
Registration phase Unknown

Product

Active substance Ciclosporin
Domain Neurological disorders
Main indication Eye disorders
Extended indication Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
Proprietary name Verkazia
Manufacturer Santen
Mechanism of action Unknown
Route of administration Ocular
Therapeutical formulation Eye drops
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Accelerated assessment
Particularity Unknown
ATMP Unknown
Submission date December 2016
Expected Registration January 2018
Orphan drug Yes
Registration phase Unknown
Additional remarks Positieve CHMP opnie 21 juli 2017.

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume < 5,100

Market share is generally not included unless otherwise stated.

References EMA
Additional remarks Vernal keratoconjunctivitis affected between 1 to 3 in 10,000 people in the European Union (EU).' (EMA) Dit zijn 5.100 patienten per 17M Nederlanders.

Expected cost per patient per year

References Medicijnkosten.nl
Additional remarks Flacon ciclosporin 10 ml, 1mg/ml: €37,04.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information